What would clearing senescent cells actually change?
You may have heard senolytics described as a way to clear "zombie cells" and slow aging. There is a real research field behind that phrase. The useful question is what has happened when the approach has been tested in people.
Some early findings give researchers a reason to keep going. Others show why a promising idea needs controlled trials. The bone and lung studies below are good examples: the main result can be quite different from the headline.
What are senescent cells?
Senescence is a state in which cells stop dividing. This can help prevent damaged cells from multiplying. Senescent cells can also release signals that affect nearby tissue, and their accumulation is one target of aging research. Senolytics are compounds studied for their ability to selectively kill these cells. [1] [2]
A 2011 experiment used genetically engineered mice with accelerated aging to remove cells carrying a senescence marker. Some age-related problems developed later. That helped establish the biological idea, but it was not a human treatment study. In 2015, researchers identified senolytic effects of dasatinib and quercetin in cell experiments and studied the combination in mice. [1] [2]
What the human studies found
Pulmonary fibrosis, 2019: fourteen people took part in a short, open-label study of dasatinib plus quercetin. Walking speed, walking distance and chair-rise performance improved from baseline, while lung function did not. One serious adverse event was reported. With no comparison group, the study could not show how much of the change was caused by treatment. Its main purpose was feasibility. [3]
Pulmonary fibrosis, 2023: a later pilot from the same trial program randomized twelve people to the drug combination or placebo. It found no meaningful between-group difference in the exploratory lung, frailty or physical-function measures. The sample was too small to settle efficacy. Researchers recorded 65 non-serious adverse events in the drug group and 22 in the placebo group; those numbers count events, not people. No serious adverse event was attributed to the combination. [4]
Bone metabolism, 2024: an open-label randomized trial studied sixty postmenopausal women over twenty weeks. The primary endpoint, a blood marker of bone breakdown called CTx, did not improve significantly compared with control. A marker of bone formation rose at weeks two and four, but the difference was no longer significant at week twenty. Two participants stopped treatment because of a prolonged QTc interval on an ECG or fatigue and other side effects. [5]
Women with higher baseline levels of a senescence-related marker appeared to respond differently in exploratory analyses. That is a question for the next study to test. It does not establish that treatment prevents fractures or that a blood test can already identify who should receive it. The trial's main result remains important when discussing those subgroup findings. [5]
Alzheimer's disease, 2023: a twelve-week pilot in five people primarily examined whether the drugs reached the central nervous system and whether the study was feasible. Dasatinib was detected in cerebrospinal fluid in four participants; quercetin was not. Prespecified cognitive measures did not change significantly. One exploratory verbal-learning measure worsened, but the study had no control group and was not designed to establish an effect on cognition. [6]
How to put those results in perspective
Cells and animals
Useful for understanding a target and testing an idea. Results do not establish a treatment effect in people.
Early human studies
Can show whether a study is practical and measure short-term responses. Small samples leave substantial uncertainty.
Controlled trials
Help separate treatment effects from other changes. The main outcome matters, including when it is negative.
Patient benefit
Needs evidence about outcomes that matter to patients. These studies do not establish longer human life.
A biomarker is a measurement that helps researchers study a biological process. Improving one measurement does not automatically mean someone will feel better, avoid a fracture or live longer. Our article on epigenetic clocks explores that same distinction with biological age tests.
What is still being studied?
The SToMP-AD registry lists a phase 2 Alzheimer's study as active and not recruiting, with estimated enrollment of 48 and no results posted as of September 29, 2026. That describes ongoing research, not a positive result. Recruitment status and completion estimates can change. [7]
A recently indexed fisetin paper describes a planned placebo-controlled study of inflammation markers in adults aged fifty or older. It is a protocol, not a report of findings. It cannot tell us yet whether fisetin improves those outcomes. Results from one compound or combination also cannot establish what another supplement will do. [8]
Questions to ask before acting on a claim
Who was studied?
- Were these cells, animals or people?
- Did the participants have a condition relevant to you?
- How many people completed the study?
What changed?
- Was there a comparison group?
- Did the primary outcome improve?
- Was the result a biomarker or a practical health outcome?
What remains open?
- What adverse events occurred?
- How long were people followed?
- Has another study confirmed the finding?
The trials discussed here used screening and monitoring, and several were designed mainly to find out whether larger studies could be done. Their results do not establish a self-treatment schedule or long-term safety. Bring the actual paper to a qualified clinician if you want to understand what it means for your circumstances.
Questions people ask
Do senolytics reverse aging in people?
The studies discussed here do not establish that senolytics reverse aging or extend human life. They test particular drugs in selected groups, often with small samples and short follow-up. A change in a biomarker needs to be distinguished from a change in health.
Did the bone trial work?
The trial did not meet its primary endpoint in the overall group. A bone-formation marker increased early but not at 20 weeks, and exploratory subgroup findings generated questions for further research. The study did not establish fracture prevention.
Is a fisetin supplement equivalent to the treatments studied?
No. Findings from dasatinib plus quercetin cannot establish the effects of fisetin or another supplement. The fisetin paper linked here is a trial protocol, which describes a planned study and contains no treatment results.
What should I ask about a senolytic claim?
Ask for the original study, who took part, the comparison group, the main outcome and the adverse events. Ask whether the finding came from cells, animals or people, and whether it would change a decision relevant to your health.
What to take away
Senolytics are worth following because the idea is being tested in people. Read the full result, including the main outcome, adverse events and limits of the study. That gives you a much better basis for a conversation than the promise of clearing "zombie cells."
The evidence
Sources checked September 29, 2026. Published studies, a trial registry and a study protocol are labelled separately below. Browse the studies in our Science library.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. The research discussed does not establish a self-treatment protocol. Any treatment decision should be made with a qualified physician. Individual results vary.